Sugi Predict

Sugi Predict / Compounds / SCHEMBL14946186

SCHEMBL14946186

SCHEMBL14946186

NCCCOCCOCCCCCOCCOCCCNc1ncnc2c1ncn2C1OC(COP(=O)(O)O)C(O)C1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 2/20 0.65
▸ TAS1R1 Q7RTX1 2/20 0.65
▸ P2RX3 P56373 3/20 0.65
▸ P2RX2 Q9UBL9 3/20 0.65
▸ DNPH1 O43598 5/20 0.64
▸ ADORA1 P30542 3/20 0.61
▸ PRKAB2 O43741 1/20 0.61
▸ TRPM2 O94759 1/20 0.61
▸ LDHA P00338 1/20 0.61
▸ ADRB2 P07550 1/20 0.61
▸ FBP1 P09467 1/20 0.61
▸ SRC P12931 1/20 0.61
▸ P2RY2 P41231 1/20 0.61
▸ P2RY1 P47900 1/20 0.61
▸ PRKAG1 P54619 1/20 0.61
▸ PRKAA2 P54646 1/20 0.61
▸ PDE4D Q08499 1/20 0.61
▸ KCNH2 Q12809 1/20 0.61
▸ PRKAA1 Q13131 1/20 0.61
▸ PDE3A Q14432 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14948866 0.98 P2RX3 (0.66) TAS1R3TAS1R1P2RX3P2RX2DNPH1
SCHEMBL15305350 0.98 P2RX3 (0.67) TAS1R3TAS1R1P2RX3P2RX2DNPH1
SCHEMBL14946188 0.93 P2RX3 (0.76) TAS1R3TAS1R1P2RX3P2RX2DNPH1
SCHEMBL216645 0.92 P2RX3 (0.70) TAS1R3TAS1R1P2RX3P2RX2DNPH1
SCHEMBL25698378 0.92 P2RX3 (0.72) TAS1R3TAS1R1P2RX3P2RX2DNPH1
SCHEMBL20705924 0.92 P2RX3 (0.72) TAS1R3TAS1R1P2RX3P2RX2DNPH1
SCHEMBL14946381 0.92 P2RX3 (0.78) TAS1R3TAS1R1P2RX3P2RX2DNPH1
SCHEMBL18574267 0.92 P2RX3 (0.78) TAS1R3TAS1R1P2RX3P2RX2DNPH1
SCHEMBL14948867 0.92 P2RX3 (0.78) TAS1R3TAS1R1P2RX3P2RX2DNPH1
SCHEMBL16340735 0.92 P2RX3 (0.78) TAS1R3TAS1R1P2RX3P2RX2DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Modema Therapeutics, Inc. (US) 2017-05-18 — — US disclosed
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2017-05-18 — — US disclosed
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNATX, INC. 2017-03-02 — — US disclosed
US-20160354493-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNATX, INC. 2016-12-08 — — US disclosed
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160354490-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-01 — — US disclosed
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2016-10-20 — — US disclosed
US-20160256573-A1 MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF MODERNATX, INC. 2016-09-08 — — US disclosed
US-20160022840-A1 HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA MODERNATX, INC. 2016-01-28 — — US disclosed
US-20160022774-A1 DIAGNOSIS AND TREATMENT OF FIBROSIS MODERNATX, INC. 2016-01-28 — — US disclosed
US-20150307542-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNATX, INC. 2015-10-29 — — US disclosed
US-20150167017-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2015-06-18 — — US disclosed
US-20140378538-A1 METHODS OF RESPONDING TO A BIOTHREAT MODERNATX, INC. 2014-12-25 — — US disclosed
US-20140371302-A1 MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES MODERNATX, INC. 2014-12-18 — — US disclosed
US-20140343129-A1 MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF MODERNATX, INC. 2014-11-20 — — US disclosed
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TAS1R3 1881/4885TAS1R1 2333/4885P2RX3 3314/4885
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TAS1R3 1881/4885TAS1R1 2333/4885P2RX3 3314/4885
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 TAS1R3 2352/4885TAS1R1 2700/4885P2RX3 736/4885
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 TAS1R3 2352/4885TAS1R1 2700/4885P2RX3 736/4885
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TAS1R3 1881/4885TAS1R1 2333/4885P2RX3 3314/4885
US-20160022774-A1 DIAGNOSIS AND TREATMENT OF FIBROSIS MMP1, COL2A1, COL1A1 TAS1R3 3494/4885TAS1R1 3571/4885P2RX3 2167/4885
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 TAS1R3 2041/4885TAS1R1 2677/4885P2RX3 2081/4885
US-20160354490-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TAS1R3 1881/4885TAS1R1 2333/4885P2RX3 3314/4885
US-20160256573-A1 MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF RNMT, NSUN2, NSUN3 TAS1R3 2010/4885TAS1R1 2100/4885P2RX3 1510/4885
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 TAS1R3 2041/4885TAS1R1 2677/4885P2RX3 2081/4885
US-20160354493-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TAS1R3 1881/4885TAS1R1 2333/4885P2RX3 3314/4885
US-20160022840-A1 HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA RNGTT, NSUN3, CPSF6 TAS1R3 4808/4885TAS1R1 4874/4885P2RX3 3487/4885
US-20150307542-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TAS1R3 1881/4885TAS1R1 2333/4885P2RX3 3314/4885
US-20140378538-A1 METHODS OF RESPONDING TO A BIOTHREAT POLRMT, RNMT, RNGTT TAS1R3 3244/4885TAS1R1 3388/4885P2RX3 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.